Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06826989 · ClinicalTrials.gov registry record · Phase 1

A Study of MK-8527 in Healthy Adult Participants (MK-8527-013)

A Phase 1 study of Healthy, sponsored by Merck Sharp & Dohme.

Completed
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT06826989: Completed Phase 1 study of Healthy, sponsored by Merck Sharp & Dohme.

NCT06826989 is a Phase 1 study of Healthy that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 8 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06826989, a Phase 1 study of Healthy, has completed, sponsored by Merck Sharp & Dohme.

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to learn how \[14C\]MK-8527 moves through a healthy person's body over time. Researchers will study how \[14C\]MK-8527 is absorbed by the body, broken down by the body, and how it leaves the body.

Primary Outcome

Urine and fecal samples will be collected to determine the cumulative percentage of radioactivity recovered from both urine and feces.

Conditions Studied

Interventions

  • DRUG [14C]MK-8527

Study Locations (1)

Wisconsin

  • Fortea CRU Madison ( 0001) - Madison

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2025-03-19
Est. Completion 2025-06-04
Phase Phase 1
Merck Sharp & Dohme

558 total trials

What the finished NCT06826989 record still lists

NCT06826989 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which [14C]MK-8527 is the first listed.

NCT06826989 reports a single indexed study location in Wisconsin.

Frequently Asked Questions

What is clinical trial NCT06826989 about?

NCT06826989 is a clinical study titled "A Study of MK-8527 in Healthy Adult Participants (MK-8527-013)". The goal of this study is to learn how \[14C\]MK-8527 moves through a healthy person's body over time. Researchers will study how \[14C\]MK-8527 is absorbed by the body, broken down by the body, and how it leaves the body.

What is the current status of trial NCT06826989?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-03-19. Estimated completion is 2025-06-04.

What conditions does trial NCT06826989 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT06826989?

The interventions under investigation include: [14C]MK-8527 (DRUG).

Who is sponsoring clinical trial NCT06826989?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06826989 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06826989's enrollment target sits among peer trials

8 1061st of 1090 higher than 18 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06826989, the US trial registry maintained by the National Library of Medicine. NCT06826989 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.